Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2011. The report details a specific share repurchase transaction executed on October 10, 2011, in accordance with shareholder authority granted at the Annual General Meeting on May 5, 2011.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback activity:
- Shares Purchased: 150,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,389.5 pence per share; lowest price paid was 1,377 pence per share.
- Treasury Holdings: Post-transaction, the Company holds 505,926,370 shares in Treasury (9.08% of total issued share capital).
- Total Voting Rights: Including unsettled purchases, Treasury holdings represent 10.00% of current total voting rights.
- Shares in Issue: 5,063,784,796 shares (excluding Treasury shares).
Material Changes
The filing does not report material changes to the Company's financial position, operations, or results compared to prior periods. The primary change reported is the reduction of outstanding shares due to the repurchase of 150,000 shares and the subsequent increase in Treasury stock holdings.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming adherence to the Financial Services Authority's Disclosure and Transparency Rules regarding share ownership disclosure.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (505,926,370) against the Company's latest annual report.
- Confirm the calculation of total voting rights (10.00% held in Treasury) based on the 5,063,784,796 shares in issue.
- Check subsequent filings for any further share repurchases or changes to the Treasury stock percentage.
- Note that this document does not contain operational or financial performance data; refer to Form 20-F for full financial statements.